Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.

[1]  C. Ahern,et al.  A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112) , 2013, Clinical Cancer Research.

[2]  J. Shay,et al.  Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton , 2013, International journal of oncology.

[3]  Kristian Cibulskis,et al.  A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. , 2012, The Journal of clinical investigation.

[4]  J. Dome,et al.  Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells , 2011, Cancer Prevention Research.

[5]  P. Houghton,et al.  Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. , 2011, Biochemical and biophysical research communications.

[6]  K. Pritchard-Jones,et al.  Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group , 2011, Pediatric blood & cancer.

[7]  D. Zagzag,et al.  Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. , 2011, Cancer research.

[8]  J. Biegel,et al.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors , 2011, Pediatric blood & cancer.

[9]  D. Zagzag,et al.  Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1 , 2010, Proceedings of the National Academy of Sciences.

[10]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[11]  C. Roberts,et al.  The role of SMARCB1/INI1 in the development of rhabdoid tumors , 2009, Cancer biology & therapy.

[12]  L. Kluwe,et al.  Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis , 2008, Clinical genetics.

[13]  H. Greulich,et al.  Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability , 2008, Molecular and Cellular Biology.

[14]  A. Protopopov,et al.  Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo , 2008, Leukemia.

[15]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[16]  F. Baas,et al.  Germline mutation of INI1/SMARCB1 in familial schwannomatosis. , 2007, American journal of human genetics.

[17]  J. Shay,et al.  Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. , 2007, Cancer research.

[18]  A. Imbalzano,et al.  Mammalian SWI/SNF complexes facilitate DNA double‐strand break repair by promoting γ‐H2AX induction , 2006, The EMBO journal.

[19]  M. Yaniv,et al.  Increased DNA Damage Sensitivity and Apoptosis in Cells Lacking the Snf5/Ini1 Subunit of the SWI/SNF Chromatin Remodeling Complex , 2006, Molecular and Cellular Biology.

[20]  J. Shay,et al.  Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer , 2006, Breast Cancer Research and Treatment.

[21]  D. Alarcon-Vargas,et al.  Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors , 2006, Oncogene.

[22]  Pablo Tamayo,et al.  Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Weissman,et al.  Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. , 2005, Cancer research.

[24]  N. Breslow,et al.  Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Shay,et al.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. , 2005, Cancer research.

[26]  D. Zagzag,et al.  Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Campisi,et al.  Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress. , 2004, Experimental cell research.

[28]  B. Scheithauer,et al.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Kastan,et al.  Disappearance of the Telomere Dysfunction-Induced Stress Response in Fully Senescent Cells , 2004, Cancer Research.

[30]  N. Carter,et al.  A DNA damage checkpoint response in telomere-initiated senescence , 2003, Nature.

[31]  T. Lange,et al.  DNA Damage Foci at Dysfunctional Telomeres , 2003, Current Biology.

[32]  W. Hahn,et al.  Erosion of the telomeric single-strand overhang at replicative senescence , 2003, Nature Genetics.

[33]  J. Biegel,et al.  Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Matthew W. Strobeck,et al.  Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1arrest associated with induction of p16ink4a and activation of RB , 2002, Oncogene.

[35]  R. Cawthon.  Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[36]  J. Shay,et al.  Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors , 2002, Oncogene.

[37]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[38]  C. Roberts,et al.  Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Finnon,et al.  Short Telomeres Result in Organismal Hypersensitivity to Ionizing Radiation in Mammals , 2000, The Journal of experimental medicine.

[40]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[41]  O. Delattre,et al.  Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. , 1999, American journal of human genetics.

[42]  G. Morin,et al.  Functional requirement of p23 and Hsp90 in telomerase complexes. , 1999, Genes & development.

[43]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[44]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[45]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[46]  Ji-Hye Park,et al.  Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage. , 2009, DNA repair.

[47]  R. Arceci.  Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy , 2006 .

[48]  J. Shay,et al.  Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors , 2002, Oncogene.

[49]  L. Chin,et al.  Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation , 2000, Nature Genetics.